Boehringer discontinues virology research program

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will discontinue its virology research program following a review of its research areas and priorities. The company said, "The demands for medical innovation are shifting significantly" in virology due to the availability of new medicines and an emphasis on prevention through vaccination, a field in which Boehringer is not active. Boehringer expects the discontinuation of its virology research program to affect about 170 employees. It also said it will close a Laval, Quebec, research facility in 1Q13. The company could not be reached for details. ...